Detalhe da pesquisa
1.
BCR::ABL1 Kinase N-lobe Mutants Confer Moderate to High Degrees of Resistance to Asciminib.
Blood
; 2024 04 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38643492
2.
Efficacy and safety of nilotinib in chronic myeloid leukaemia patients who failed to achieve a treatment-free remission period after imatinib discontinuation: Results of the French Nilo post-STIM study.
Br J Haematol
; 201(6): 1116-1124, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37004981
3.
Treatment-free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5-year analysis of DASFREE.
Br J Haematol
; 202(5): 942-952, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37246588
4.
Dasatinib plus Peg-Interferon alpha 2b combination in newly diagnosed chronic phase chronic myeloid leukaemia: Results of a multicenter phase 2 study (DASA-PegIFN study).
Br J Haematol
; 200(2): 175-186, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36214090
5.
A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs.
Blood
; 138(21): 2031-2041, 2021 11 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-34407542
6.
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.
N Engl J Med
; 381(24): 2315-2326, 2019 12 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31826340
7.
Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trial.
Haematologica
; 107(12): 2859-2869, 2022 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35615931
8.
Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia.
Am J Hematol
; 97(11): 1419-1426, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36054756
9.
Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients.
Br J Haematol
; 194(2): 393-402, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34195988
10.
Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.
Blood
; 132(4): 393-404, 2018 07 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-29567798
11.
Kinetics of molecular recurrence after tyrosine kinase inhibitor cessation in chronic phase chronic myelogenous leukaemia patients.
Br J Haematol
; 204(4): 1536-1539, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38323384
12.
Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome.
Br J Haematol
; 187(3): 337-346, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31271217
13.
Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study.
Blood
; 129(7): 846-854, 2017 02 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-27932374
14.
Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia.
Haematologica
; 104(1): 93-101, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30093398
15.
Poor prognosis of chromosome 7 clonal aberrations in Philadelphia-negative metaphases and relevance of potential underlying myelodysplastic features in chronic myeloid leukemia.
Haematologica
; 104(6): 1150-1155, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30573507
16.
Treatment-free remission with first- and second-generation tyrosine kinase inhibitors.
Am J Hematol
; 94(3): 346-357, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30394563
17.
Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group.
Cancer
; 124(14): 2956-2963, 2018 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29723417
18.
How I manage relapse of chronic myeloid leukaemia after stopping tyrosine kinase inhibitor therapy.
Br J Haematol
; 180(1): 24-32, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29048128
19.
Impact of NFE2 mutations on AML transformation and overall survival in patients with myeloproliferative neoplasms.
Blood
; 138(21): 2142-2148, 2021 11 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-33945619
20.
Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia.
Cancer
; 123(22): 4403-4410, 2017 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28743166